Sure, here's a rewritten version of the article with the requested adjustments:
The settlement, nearly seven months following the U.S. Supreme Court's decision, aims to address the opioid crisis that's claimed over 700,000 lives in the U.S. over the last two decades. The latest agreement, worth approximately $7.4 billion, sees a coalition of states and other parties reaching an in-principle accord with the Sackler family and their company, Purdue Pharma.
The Sacklers, without filing for bankruptcy themselves, will cough up a staggering $6.5 billion spread over fifteen years, with Purdue adding nearly $900 million to the pot during the same period. This payment structure ensures substantial funds are distributed in the initial three years, with the Sacklers paying $1.5 billion, followed by $500 million, then $500 million, and finally $400 million after three years.
The settlement marks the end of the Sacklers' influence over Purdue Pharma's opioid operations. It prohibits them from marketing or lobbying opioids in the U.S. and strips them of their opioid sales rights. Meanwhile, a board of trustees selected by the states will decide Purdue's fate, with the company being continuously monitored.
Moreover, this agreement mandates the disclosure of over 30 million documents linked to Purdue and the Sacklers' opioid business. This includes adherence to the 2007 State Attorneys General Consent Judgments. Additionally, the settlement funding will be distributed to various parties, including affected individuals, states, local governments, and those already suing the Sacklers or Purdue, provided court approval is obtained.
This settlement represents the most significant financial commitment to date from individuals linked to the opioid crisis. State Attorneys General have displayed their determination to bring accountability to those who contributed to and worsened the opioid epidemic.
The Sacklers, despite not filing for bankruptcy, are now involved in a significant business transformation, as they agreed to pay a substantial sum over fifteen years. This financial commitment from the Sacklers and Purdue Pharma will significantly impact the ongoing legal proceedings and distributions to affected parties in the opioid crisis business-related lawsuits.
